Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Epsilogen, a UK-based spinout of King’s College London working on cancer treatments that exploit immunoglobulin E antibodies, pocketed £30.75m ($41.2m) in a series B round backed by commercialisation firm Epidarex Capital yesterday. The round was led by Novartis Venture Fund on behalf of pharmaceutical firm Novartis, and also included Alsa Ventures, 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property. Epsilogen, then known as Item Therapeutics, previously closed a $6.4m series A round in 2018 backed…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
